Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
TTK Healthcare has reported total income of Rs. 222.58 crore during the period ended September 30, 2025
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
Subscribe To Our Newsletter & Stay Updated
